Rakovina Therapeutics Inc. (RKV.V)
- Previous Close
0.0500 - Open
0.0500 - Bid 0.0550 x --
- Ask 0.0600 x --
- Day's Range
0.0450 - 0.0650 - 52 Week Range
0.0400 - 0.2300 - Volume
2,854,767 - Avg. Volume
307,304 - Market Cap (intraday)
5.417M - Beta (5Y Monthly) -0.32
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0500 - Earnings Date May 28, 2025 - Jun 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.40
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. Its preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Variational AI Inc. to identify and develop novel small-molecule therapies against DNA-damage response (DDR) targets for the treatment of cancer. Rakovina Therapeutics Inc. was formerly known as Vincero Capital Corp. The company is headquartered in Vancouver, Canada. Rakovina Therapeutics Inc. operates as a subsidiary of NewGen Therapeutics, Inc.
www.rakovinatherapeutics.comRecent News: RKV.V
View MorePerformance Overview: RKV.V
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RKV.V
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RKV.V
View MoreValuation Measures
Market Cap
5.42M
Enterprise Value
5.52M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.26
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-34.30%
Return on Equity (ttm)
-89.48%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-3.31M
Diluted EPS (ttm)
-0.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
255.05k
Total Debt/Equity (mrq)
45.41%
Levered Free Cash Flow (ttm)
-1.36M